價格 | ¥112 | ¥170 | ¥298 |
包裝 | 2mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:氯谷胺 | 英文名稱:Loxiglumide |
CAS:107097-80-3 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.81% | 產(chǎn)品類別: 抑制劑 |
貨號: T2312 |
名稱 | Loxiglumide |
描述 | Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor. |
激酶實驗 | Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH?8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 4.61 mg/mL (10 mM) |
關(guān)鍵字 | CCK Receptor | Inhibitor | Loxiglumide | CR1505 | CR 1505 | inhibit | Cholecystokinin Receptor |
相關(guān)產(chǎn)品 | N-Cbz-DL-tryptophan | GV150013 | Proglumide | GV-150013X | Gastrin I (human) acetate | Spiroglumide | Itriglumide | A-65186 | CCK Octapeptide, non-sulfated acetate | WAY-620645 | PHA-767491 | Lintitript |
相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | NO PAINS 化合物庫 | GPCR靶點分子庫 | 膜蛋白靶向化合物庫 | 疼痛相關(guān)化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
陜西締都醫(yī)藥化工有限公司
|
2024-12-18 | |
詢價 |
VIP2年
|
湖北寶凌化工科技有限公司
|
2025-02-06 | |
詢價 |
VIP4年
|
湖北辰心藥業(yè)有限公司
|
2025-01-03 | |
¥1803.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |